Email
Location
- Advanced (2024) — A-PONTE: ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication
- Proof of concept (2012) — ALKVAX: Market potentials of ALK vaccination as a new strategy for the cure of ALK positive tumors such as lymphoma, lung carcinoma and neuroblastoma
- Starting (2008) — LUNELY: ALK as a common target for the pathogenesis and therapy in lymphoma, lung carcinoma and neuroblastoma